(GILD) Gilead Sciences - Ratings and Ratios
HIV,AIDS,Hepatitis,COVID,Cancer
GILD EPS (Earnings per Share)
GILD Revenue
Description: GILD Gilead Sciences
Gilead Sciences Inc. is a leading biopharmaceutical company that focuses on developing and commercializing innovative medicines for life-threatening diseases. The companys product portfolio includes treatments for HIV/AIDS, COVID-19, viral hepatitis, oncology, and other serious medical conditions.
From a business perspective, Gilead Sciences has a diverse revenue stream with a strong presence in the global market. The companys HIV franchise, which includes products like Biktarvy and Truvada, continues to be a significant contributor to its revenue. Additionally, Gilead Sciences has expanded its oncology portfolio through the acquisition of companies like Kite Pharma, which has added products like Yescarta to its portfolio.
In terms of key performance indicators (KPIs), Gilead Sciences has a strong track record of delivering revenue growth, with a 5-year CAGR of around 10%. The companys operating margin is also impressive, at around 40%. Furthermore, Gilead Sciences has a significant R&D investment, with around 20% of its revenue being reinvested into research and development. The companys return on equity (RoE) is also noteworthy, at 31.71%, indicating a strong ability to generate profits from shareholder equity.
From a valuation perspective, Gilead Sciences has a market capitalization of around $142 billion, with a price-to-earnings (P/E) ratio of 24.06. The companys forward P/E ratio is lower, at 14.31, suggesting that analysts expect earnings growth in the future. Overall, Gilead Sciences appears to be a well-established player in the biopharmaceutical industry, with a strong product portfolio and a commitment to innovation.
GILD Stock Overview
| Market Cap in USD | 146,242m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1992-01-22 |
GILD Stock Ratings
| Growth Rating | 92.7% |
| Fundamental | 75.9% |
| Dividend Rating | 64.1% |
| Return 12m vs S&P 500 | 17.4% |
| Analyst Rating | 4.13 of 5 |
GILD Dividends
| Dividend Yield 12m | 2.91% |
| Yield on Cost 5y | 5.95% |
| Annual Growth 5y | 2.52% |
| Payout Consistency | 100.0% |
| Payout Ratio | 40.6% |
GILD Growth Ratios
| Growth Correlation 3m | 63% |
| Growth Correlation 12m | 89.5% |
| Growth Correlation 5y | 86.8% |
| CAGR 5y | 25.58% |
| CAGR/Max DD 3y | 0.96 |
| CAGR/Mean DD 3y | 3.39 |
| Sharpe Ratio 12m | 1.53 |
| Alpha | 0.13 |
| Beta | 0.370 |
| Volatility | 24.03% |
| Current Volume | 6379.7k |
| Average Volume 20d | 5639.5k |
| Stop Loss | 108.8 (-3.1%) |
| Signal | 0.22 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (6.31b TTM) > 0 and > 6% of Revenue (6% = 1.73b TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 3.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.23% (prev 5.53%; Δ 6.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 9.87b > Net Income 6.31b (YES >=105%, WARN >=100%) |
| Net Debt (19.80b) to EBITDA (10.97b) ratio: 1.80 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.25b) change vs 12m ago 0.32% (target <= -2.0% for YES) |
| Gross Margin 78.53% (prev 75.72%; Δ 2.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.81% (prev 51.89%; Δ 0.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.19 (EBITDA TTM 10.97b / Interest Expense TTM 1.00b) >= 6 (WARN >= 3) |
Altman Z'' 2.42
| (A) 0.06 = (Total Current Assets 14.72b - Total Current Liabilities 11.19b) / Total Assets 55.72b |
| (B) 0.20 = Retained Earnings (Balance) 11.32b / Total Assets 55.72b |
| (C) 0.15 = EBIT TTM 8.20b / Avg Total Assets 54.65b |
| (D) 0.31 = Book Value of Equity 11.31b / Total Liabilities 36.13b |
| Total Rating: 2.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.88
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 5.64% = 2.82 |
| 3. FCF Margin 32.46% = 7.50 |
| 4. Debt/Equity 1.27 = 1.75 |
| 5. Debt/Ebitda 2.27 = -0.53 |
| 6. ROIC - WACC (= 6.50)% = 8.12 |
| 7. RoE 32.94% = 2.50 |
| 8. Rev. Trend 21.51% = 1.61 |
| 9. EPS Trend 2.15% = 0.11 |
What is the price of GILD shares?
Over the past week, the price has changed by -1.92%, over one month by -4.20%, over three months by +4.67% and over the past year by +39.20%.
Is Gilead Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GILD is around 130.86 USD . This means that GILD is currently undervalued and has a potential upside of +16.57% (Margin of Safety).
Is GILD a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GILD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.9 | 11.3% |
| Analysts Target Price | 124.9 | 11.3% |
| ValueRay Target Price | 143.2 | 27.6% |
Last update: 2025-09-13 05:02
GILD Fundamental Data Overview
CCE Cash And Equivalents = 5.21b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 23.3849
P/E Forward = 13.6054
P/S = 5.0668
P/B = 7.4329
P/EG = 0.2217
Beta = 0.379
Revenue TTM = 28.86b USD
EBIT TTM = 8.20b USD
EBITDA TTM = 10.97b USD
Long Term Debt = 22.14b USD (from longTermDebt, last quarter)
Short Term Debt = 2.81b USD (from shortTermDebt, last quarter)
Debt = 24.95b USD (Calculated: Short Term 2.81b + Long Term 22.14b)
Net Debt = 19.80b USD (from netDebt column, last quarter)
Enterprise Value = 165.97b USD (146.24b + Debt 24.95b - CCE 5.21b)
Interest Coverage Ratio = 8.19 (Ebit TTM 8.20b / Interest Expense TTM 1.00b)
FCF Yield = 5.64% (FCF TTM 9.37b / Enterprise Value 165.97b)
FCF Margin = 32.46% (FCF TTM 9.37b / Revenue TTM 28.86b)
Net Margin = 21.87% (Net Income TTM 6.31b / Revenue TTM 28.86b)
Gross Margin = 78.53% ((Revenue TTM 28.86b - Cost of Revenue TTM 6.20b) / Revenue TTM)
Tobins Q-Ratio = 14.68 (Enterprise Value 165.97b / Book Value Of Equity 11.31b)
Interest Expense / Debt = 1.02% (Interest Expense 254.0m / Debt 24.95b)
Taxrate = 30.58% (211.0m / 690.0m)
NOPAT = 5.69b (EBIT 8.20b * (1 - 30.58%))
Current Ratio = 1.32 (Total Current Assets 14.72b / Total Current Liabilities 11.19b)
Debt / Equity = 1.27 (Debt 24.95b / last Quarter total Stockholder Equity 19.68b)
Debt / EBITDA = 2.27 (Net Debt 19.80b / EBITDA 10.97b)
Debt / FCF = 2.66 (Debt 24.95b / FCF TTM 9.37b)
Total Stockholder Equity = 19.16b (last 4 quarters mean)
RoA = 11.33% (Net Income 6.31b, Total Assets 55.72b )
RoE = 32.94% (Net Income TTM 6.31b / Total Stockholder Equity 19.16b)
RoCE = 19.86% (Ebit 8.20b / (Equity 19.16b + L.T.Debt 22.14b))
RoIC = 12.90% (NOPAT 5.69b / Invested Capital 44.12b)
WACC = 6.41% (E(146.24b)/V(171.19b) * Re(7.38%)) + (D(24.95b)/V(171.19b) * Rd(1.02%) * (1-Tc(0.31)))
Shares Correlation 3-Years: -40.00 | Cagr: -0.04%
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.65% ; FCFE base≈8.38b ; Y1≈8.03b ; Y5≈7.83b
Fair Price DCF = 112.6 (DCF Value 139.67b / Shares Outstanding 1.24b; 5y FCF grow -5.51% → 3.0% )
EPS Correlation: 2.15 | EPS CAGR: 2.07% | SUE: 0.26 | # QB: 0
Revenue Correlation: 21.51 | Revenue CAGR: 0.20% | SUE: 0.43 | # QB: 0
Additional Sources for GILD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle